Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) reported EBT Margin of 135.29% for Q1 2026, down 2738.0% year-over-year from 5.13% in Q1 2025, and down 119.63% on a QoQ basis from 61.6% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 11 years of EBT Margin data on file, last reported at 135.29% in Q1 2026.
- Quarterly EBT Margin fell 2738.0% year-over-year to 135.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 90.37% (down 9312.0% YoY) and the FY2025 annual result came in at 84.84%, down 8413.0% from the prior year.
- EBT Margin eased to 135.29% in Q1 2026 per RARE's latest filing, from 61.6% in the prior quarter.
- Across five years, EBT Margin topped out at 261.28% in Q4 2024 and bottomed at 263.3% in Q3 2022.
- The 5-year median for EBT Margin is 135.29% (2026), against an average of 112.66%.
- The widest annual swing landed in 2024, when EBT Margin surged 36150 bps; it then slumped 32288 bps in 2025.
- Tracing RARE's EBT Margin over 5 years: stood at 148.32% in 2022, then surged by 32 bps to 100.22% in 2023, then surged by 361 bps to 261.28% in 2024, then tumbled by 124 bps to 61.6% in 2025, then tumbled by 120 bps to 135.29% in 2026.
- Per Business Quant, the three latest RARE EBT Margin figures stand at 135.29% (Q1 2026), 61.6% (Q4 2025), and 112.26% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -135.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -135.29% |
| Dec 31, 2025 | -61.60% |
| Sep 30, 2025 | -112.26% |
| Jun 30, 2025 | -68.47% |
| Mar 31, 2025 | -107.91% |
| Dec 31, 2024 | 261.28% |
| Sep 30, 2024 | -95.50% |
| Jun 30, 2024 | -88.92% |
| Mar 31, 2024 | -156.41% |
| Dec 31, 2023 | -100.22% |
| Sep 30, 2023 | -162.16% |
| Jun 30, 2023 | -146.89% |
| Mar 31, 2023 | -162.67% |
| Dec 31, 2022 | -148.32% |
| Sep 30, 2022 | -263.30% |
| Jun 30, 2022 | -176.69% |
| Mar 31, 2022 | -189.86% |
| Dec 31, 2021 | -149.63% |
| Sep 30, 2021 | -89.18% |
| Jun 30, 2021 | -140.23% |
| Mar 31, 2021 | -136.59% |
| Dec 31, 2020 | -26.15% |
| Sep 30, 2020 | -84.12% |
| Jun 30, 2020 | 41.70% |
| Mar 31, 2020 | -326.68% |
| Dec 31, 2019 | -256.35% |
| Sep 30, 2019 | -436.83% |
| Jun 30, 2019 | -409.79% |
| Mar 31, 2019 | -531.26% |
| Dec 31, 2018 | -539.33% |
| Sep 30, 2018 | -740.14% |
| Jun 30, 2018 | -411.33% |
| Mar 31, 2018 | 283.71% |
| Dec 31, 2017 | -4,664.19% |
| Sep 30, 2017 | -40,011.62% |
| Dec 31, 2016 | -1,425,040.00% |
| Sep 30, 2016 | -58,474.77% |
| Jun 30, 2016 | -334,841.18% |